In pursuit of natural product leads: Synthesis and biological evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4- carboxylic acid (A-33853) and its analogues: Discovery of N-(2-benzoxazol-2- ylphenyl)benzamides as novel antileishmanial chemotypes

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7344-7347

  Tipparaju, Suresh K ^a   Joyasawal, Sipak ^a   Pieroni, Marco ^a   Kaiser, Marcel ^b   Brun, Reto ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 HYDROXY 2 [(3 HYDROXYPYRIDINE 2 CARBONYL)AMINO]PHENYL]BENZOXAZOLE 4 CARBOXYLIC ACID; A 33853; ANTILEISHMANIAL AGENT; BENZAMIDE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; MILTEFOSINE; N (2 BENZOXAZOL 2 YLPHENYL)BENZAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; LEISHMANIA DONOVANI; NONHUMAN; PLASMODIUM FALCIPARUM; REACTION ANALYSIS; TRYPANOSOMA CRUZI; TRYPANOSOMA RHODESIENSE;

ANIMALS; ANTIPROTOZOAL AGENTS; BENZAMIDES; BENZOXAZOLES; BIOLOGICAL FACTORS; DRUG DISCOVERY; LEISHMANIA DONOVANI; MACROPHAGES; MICE; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; STEREOISOMERISM;

EID: 57349163113     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801241n     Document Type: Article

References (19)

1. http://www.who.int/tdr/diseases/leish/diseaseinfo.htm.
2. Chung, M. C.; Ferreira, E. I.; Santos, J. L.; Giarolla, J.; Rando, D. G.; Almeida, A. E.; Bosquesi, P. L.; Menegon, R. F.; Balu, L. Prodrugs for the treatment of neglected diseases. Molecules 2008, 13, 616-677.
3. http://www.dndi.org/cms/public_html/insidecategoryListing.asp?CategoryId= 89.
4. (a) Desjeux, P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microb. 2004, 27, 305-318.
5. (b) Croft, S. L.; Yardley, V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 2002, 8, 319-342.
6. (c) Berman, J. D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 1997, 24, 684-703.
7. (a) Croft, S. L.; Seifert, K.; Yardley, V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 2006, 123, 399-410.
8. (b) Murray, H. W.; Berman, J. D.; Davies, C. R.; Saravia, N. G. Advances in leishmaniasis. Lancet 2005, 366, 1561-1577.
9. Poola, N. R.; Kalis, M.; Plakogiannis, F. M.; Taft, D. R. Characterization of pentamidine excretion in the isolated perfused rat kidney. J. Antimicrob. Chemother. 2003, 52, 397-404.
10. (a) Herwaldt, B. L. Miltefosine - the long-awaited therapy for visceral leishmaniasis. N. Engl. J. Med. 1999, 341, 1840-1842.
11. (b) Sindermann, H.; Engel, K. R.; Fischer, C.; Bommer, W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 2004, 39, 1520-1523.
12. (a) den Boer, M.; Davidson, R. N. Treatment options for visceral leishmaniasis. Expert Rev. Anti-Infect. Ther. 2006, 4, 187-197.
13. (b) Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 2007, 5, 873-882.
14. Jha, T. K.; Sundar, S.; Thakur, C. P.; Felton, J. M.; Sabin, A. J.; Horton, J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 2005, 73, 1005-1011.
15. Michel, K. H.; Boeck, L. D.; Hoehn, M. M.; Jones, N. D.; Chaney, M. O. The discovery, fermentation, isolation, and structure of antibiotic A-33853 and its tetraacetyl derivative. J. Antibiot. 1984, 37, 441-445.
16. (a) Tipparaju, S. K.; Mulhearn, D. C.; Klein, G. M.; Chen, Y.; Tapadar, S.; Bishop, M. H.; Yang, S.; Chen, J.; Ghassemi, M.; Santarsiero, B. D.; Cook, J. L.; Johlfs, M.; Mesecar, A. D.; Johnson, M. E.; Kozikowski, A. P. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase. ChemMedChem 2008, 3, 1250-1268.
17. (b) Tipparaju, S. K.; Joyasawal, S.; Forrester, S.; Mulhearn, D. C.; Pegan, S.; Johnson, M. E.; Mesecar, A. D.; Kozikowski, A. P. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase. Bioorg. Med. Chem. Lett. 2008, 18, 3565-3569.
18. Chang, J. Z. K.; Pan, S. Synthesis of 2-arylbenzoxazoles via DDQ promoted oxidative cyclization of phenolic Schiff bases - a solution-phase strategy for library synthesis. Tetrahedron Lett. 2002, 43, 951-954.
19. Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Pâerez, L. M.; Johansson, N. G.; Gonzâalez- Pacanowska, D.; Gilbert, I. H. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. J. Med. Chem. 2005, 48, 5942-5954.